Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies
International Journal of Molecular Sciences · 28.05.2025 · 26 (11) · 5173
DOI: 10.3390/ijms26115173 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.05.2025. Verfasst von Alicja Forma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Forensic Medicine, Medical University of Lublin, ul. Jaczewskiego 8b, 20-090 Lublin, Poland. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 144-mal zitiert (Crossref) und nennt 322 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Thyroid cancer (TC) invariably remains the most prevalent endocrine cancer in the world. Major histological forms of TC include papillary (PTC), follicular (FTC), medullary (MTC), and anaplastic thyroid carcinoma (ATC), each of which has a unique clinical and molecular profile. The incidence rate of TC is higher in females, and unfortunately, it has tended to increase over the last several years. Yet the treatment of advanced or aggressive TC forms has improved recently because of developments in immunotherapy and targeted medicines, including PD-1 inhibitors and tyrosine kinase inhibitors (e.g., lenvatinib, sorafenib). Imaging, fine-needle aspiration biopsies, and molecular testing are implemented in the diagnostic process, e.g., in search of mutations that might affect prognosis and provide the most successful treatment option. Chemotherapy, immunotherapy, radioactive iodine therapy (RAI), surgery (such as a total thyroidectomy), and molecularly targeted therapies are currently standard treatment modalities in TC. Optimizing patient outcomes requires better diagnostic precision and individualized treatment regimens based on the genetic profile and tumor subtype. To improve survival and quality of life, it is critical to comprehend the complex etiology of TC and the changing therapeutic landscape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Forensic Medicine, Medical University of Lublin, ul. Jaczewskiego 8b, 20-090 Lublin, Poland.
- Department of Correct, Clinical, and Imaging Anatomy, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland.
- Department of Analytical Chemistry, Medical University of Lublin, Chodźki 4A, 20-093 Lublin, Poland.
ORCID-Profile: Alicja Forma, Weronika Pająk, Jolanta Flieger, Barbara Teresińska, Jacek Baj
Zitieren
APA
Forma, A., Kłodnicka, K., Pająk, W., Flieger, J., Teresińska, B., Januszewski, J., & Baj, J. (2025). Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies. International Journal of Molecular Sciences, 26(11), 5173. https://doi.org/10.3390/ijms26115173
Vancouver
Forma A, Kłodnicka K, Pająk W, Flieger J, Teresińska B, Januszewski J, et al. Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies. International Journal of Molecular Sciences. 2025;26(11):5173. doi:10.3390/ijms26115173
BibTeX
@article{Forma2025,
author = {Forma, Alicja and Kłodnicka, Karolina and Pająk, Weronika and Flieger, Jolanta and Teresińska, Barbara and Januszewski, Jacek and Baj, Jacek},
title = {Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {11},
pages = {5173},
doi = {10.3390/ijms26115173}
}
EUVIMED